Table 2 Comparison of disease outcomes among PCR confirmed COVID-19 patients on the basis of basic demographic characteristics, coagulation profile, and disease severity (n = 66)
Clinical outcome | p value** | |||
|---|---|---|---|---|
Mortality (n = 34) | Recovery (n = 29) | LAMA* (n = 3) | ||
Frequency (%) | ||||
Age | ||||
55 years or less | 07 (38.9) | 10 (55.6) | 01 (5.5) | 0.39 |
56 years and above | 27 (56.3) | 19 (39.5) | 02 (4.2) | |
Sex | ||||
Male | 25 (55.6) | 17 (37.7) | 03 (6.7) | 0.25 |
Female | 09 (42.9) | 12 (57.1) | 0 | |
Disease severity | ||||
Mild to moderate | 02 (25) | 05 (62.5) | 01 (12.5) | 0.09 |
Severe | 05 (35.7) | 09 (64.3) | 0 | |
Critical | 27 (61.4) | 15 (34.1) | 02 (4.5) | |
Mechanical ventilation | 10 (83.3) | 02 (16.7) | 0 | 0.03 |
Pulmonary embolism | 10 (31.3) | 20 (62.5) | 02 (6.2) | 0.03 |
Non-pulmonary thrombosis | 04 (80.0) | 0 | 01 (20.0) | 0.05 |
Steroids | 34 (52.3) | 28 (43.1) | 03 (4.6) | 0.48 |
Tocilizumab | 07 (46.7) | 07 (46.7) | 01 (6.6) | 0.95 |
Remdesivir | 24 (57.1) | 16 (38.1) | 02 (4.8) | 0.44 |